Read the latest updates from MitoRx Therapeutics

• MitoRx adds Babraham in Cambridge to its Oxford obesity drug capability – Business Weekly

  • In The Media
  • Posted 8 July, 2026
  Read More
• Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies – Clarivate

  • In The Media
  • Posted 22 June, 2026
  Read More
• MTRX31 restores mitochondrial metabolism in obesity – BioWorld

  • In The Media
  • Posted 11 June, 2026
  Read More
• MitoRx’s new obesity drug targets metabolism, not appetite – Longevity Technology

  • In The Media
  • Posted 11 June, 2026
  Read More
• MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth

  • Press Release
  • Posted 9 June, 2026
  Read More
• MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions

  • Press Release
  • Posted 8 June, 2026
  Read More
• Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum, June 5

  • Event
  Read More
• American Diabetes Association Scientific Sessions 2026, June 5-8

  • Event
  Read More
• Myo-004 (MTRX31) induces bodyweight loss in DIO at thermoneutrality by switching metabolism from fat to carbohydrate oxidation

  • Publication
  • Posted 1 June, 2026
  Read More
• European Association for the Study of Diabetes (EASD), 28 September – 2 October

  • Event
  Read More